In the EMILIA study, people receiving Kadcyla survived a median of 5.8 months longer compared to those taking Tykerb and Xeloda.
FORBES: A Triumph In Breast Cancer -- And Another Expensive Drug
应用推荐
模块上移
模块下移
不移动